ArticleCureus2026
Durable Complete Response Following Nivolumab Discontinuation in Human Papillomavirus (HPV)-Positive Oropharyngeal Carcinoma Complicated by Bullous Pemphigoid: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors have improved outcomes in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), although durable complete responses (CRs) remain uncommon. The optimal duration of immunotherapy is not yet established. We report the case of a 69-year-old female smoker diagnosed in November 2015 with human papillomavirus (HPV)16-positive squamous cell carcinoma of the oropharynx (base of tongue), staged cT2N2bM0. Following induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil, and concurrent chemoradiotherapy with cisplatin, persistent disease was confirmed by biopsy. In December 2016, she underwent extensive surgery that included partial pharyngectomy with tracheostomy + hemiglossectomy + bilateral neck dissection + microvascular free flap reconstruction with positive margins (ypT4aN2R1). Following surgery with positive margins, complementary systemic therapy was administered (paclitaxel, followed by cetuximab combined with methotrexate). In 2019, the patient presented with locoregional cutaneous recurrence, which required hemostatic palliative radiotherapy. Nivolumab was initiated in December 2019, and a CR was achieved about two months later, by February 2020. Treatment was discontinued in February 2021 due to immune-related toxicity (bullous pemphigoid, Common Terminology Criteria for Adverse Events v5.0, grade 3). Remarkably, the patient has maintained a CR for more than four years after discontinuation of immunotherapy, as confirmed by imaging in 2025. This case highlights the potential for durable CRs after immunotherapy discontinuation in heavily pretreated HPV-positive HNSCC, raising important questions regarding optimal treatment duration, patient selection, and the role of immune-related adverse events as a potential marker of response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.